Challenges and opportunities of drug repositioning

Trends in Pharmacological Sciences

Volumn 34, Issue 5, 2013, Pages 267-272

  Novac, Natalia ^a  

^a MERCK KGAA   (Germany)

Author keywords

compound reprofiling; extended profiling repurposing; new use of old drugs; repositioning

Indexed keywords

BIOTECHNOLOGY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG PROGRAM; DRUG REPOSITIONING; DRUG RESEARCH; DRUG USE; DRUG UTILIZATION; GOVERNMENT REGULATION; HUMAN; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW;

DRUG INDUSTRY; DRUG REPOSITIONING; HUMANS;

EID: 84876888105     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.03.004     Document Type: Review

References (37)

1. H.J. Federsel Handing over the baton: connecting medicinal chemistry with process R&D Drug News Perspect. 21 2008 193 199
2. J.A. DiMasi Trends in risks associated with new drug development: success rates for investigational drugs Clin. Pharmacol. Ther. 87 2010 272 277
3. B.M. Padhy, and Y.K. Gupta Drug repositioning: re-investigating existing drugs for new therapeutic indications J. Postgrad. Med. 57 2011 153 160
4. M. Liebowitz Safety and efficacy of AV608 in subjects with social anxiety disorder 47th Annual NCDEU Meeting June 11-14, 2007, Boca Raton, FL 2007
5. A. Sinclair Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) Lupus 16 2007 972 980
6. M. Dall'Era Mycophenolate mofetil in the treatment of systemic lupus erythematosus Curr. Opin. Rheumatol. 23 2011 454 458
7. G. Zandman-Goddard Novel approaches to therapy for systemic lupus erythematosus: update 2005 Expert Rev. Clin. Immunol. 1 2005 223 238
8. D. Patel, and J.D. Goldman-Levine Doxepin (silenor) for insomnia Am. Fam. Physician 84 2011 453 454
9. Anon Low-dose doxepin (Silenor) for insomnia Med. Lett. Drugs Ther. 52 2010 79 80
10. C. Beaudry, and J. Levasseur What influences the survival of Canadian biotechnology firms Paper presented at the DRUID 2011 on Innovation, Strategy and Structure - Organisations, Institutions, Systems and Regions June 15-17, 2011 2011 Copenhagen Business School Denmark
11. J. Zhang, and N. Patel The Dynamics of California's Biotechnology Industry 2005 Public Policy Institute of California
12. R.J. Rickles Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening Mol. Cancer Ther. 11 2012 1432 1442
13. S. Lin Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators Assay Drug Dev. Technol. 8 2010 669 684
14. C.M. Rohloff DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months J. Diabetes Sci. Technol. 2 2008 461 467
15. Arrowhead Conferences Drug Repositioning: New Technologies, Business Models and Strategies for Successful Development 2011 Arrowhead Conferences
16. T. Reilly Drug repositioning Drug Discov. 2 2006 10 12
17. Anon Mifepristone (Korlym) for Cushing's syndrome Med. Lett. Drugs Ther. 54 2012 46 47
18. R.D. Clark Glucocorticoid receptor antagonists Curr. Top. Med. Chem. 8 2008 813 838
19. C.G. McMahon Dapoxetine: a new option in the medical management of premature ejaculation Ther. Adv. Urol. 4 2012 233 251
20. S. Fowler Reversal of soft-tissue anesthesia in asymptomatic endodontic patients: a preliminary, prospective, randomized, single-blind study J. Endod. 37 2011 1353 1358
21. K.G. Khidhir The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias FASEB J. 27 2013 557 567
22. S.J. Matthews, and C. McCoy Thalidomide: a review of approved and investigational uses Clin. Ther. 25 2003 342 395
23. J.C. Cappelleri Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function Urology 56 2000 477 481
24. M. Manconi Dissociation of periodic leg movements from arousals in restless legs syndrome Ann. Neurol. 71 2012 834 844
25. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
26. C.M. Campbell Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy Pain 153 2012 1815 1823
27. D.E. McNeil Duchenne muscular dystrophy: drug development and regulatory considerations Muscle Nerve 41 2010 740 745
28. J. Kaye From patients to partners: participant-centric initiatives in biomedical research Nat. Rev. Genet. 13 2012 371 376
29. I. Melnikova Rare diseases and orphan drugs Nat. Rev. Drug Discov. 11 2012 267 268
30. K. Marusina The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning Drug Discov. Today Ther. Strateg. 8 2011 77 83
31. T.I. Oprea Drug repurposing from an academic perspective Drug Discov. Today Ther. Strateg. 8 2011 61 69
32. Clinical Operations (PH152) Benchmarking Per-patient Trial Costs, Staffing and Adaptive Design 2011 Cutting Edge Information
33. J.E. Butrynski Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor N. Engl. J. Med. 363 2010 1727 1733
34. E.L. Kwak Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 363 2011 1693 1703
35. A.T. Shaw Crizotinib Nat. Rev. Drug Discov. 10 2011 897 898
36. H. Mano ALKoma: a cancer subtype with a shared target Cancer Discov. 2 2012 495 502
37. E.L. Tobinick The value of drug repositioning in the current pharmaceutical market Drug News Perspect. 22 2009 119 125